FFAR2 and metabolic dysfunction-associated steatotic liver disease: FFAR2 deficiency exacerbated NAFLD/NASH without affecting the obese phenotype or peripheral glucose tolerance, which is not consistent with the results of a previous study, demonstrating that FFAR2 deficiency exacerbates obesity and glucose intolerance [16, 34].